Zobrazeno 1 - 10
of 21
pro vyhledávání: '"C. F. Pollera"'
Autor:
Diana Giannarelli, Fabrizio Nelli, Luca Moscetti, Isabella Sperduti, D. Padalino, C. F. Pollera
Publikováno v:
Scopus-Elsevier
ResearcherID
ResearcherID
The aim of the study was to describe in detail the impact of aging and comorbidities on safety and efficacy of gemcitabine-cisplatin in the subset of elderly with advanced NSCLC. We report the results of our study which enrolled patients aged over 65
Autor:
Francesco Cognetti, Anna Ceribelli, Alain Gelibter, Michele Milella, C. F. Pollera, Isabella Sperduti, Luca Moscetti
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 131:783-788
Purpose: Patients with advanced non-small-cell lung cancer (NSCLC) have a short life expectancy; therefore, in addition to increasing their survival, improving their quality of life (QoL) is also an important treatment goal. Methods: We evaluated the
Autor:
C F Pollera
Publikováno v:
Journal of Clinical Oncology. 15:2172-2174
Publikováno v:
Journal of experimentalclinical cancer research : CR. 24(1)
Anaplastic thyroid carcinoma is a rare disease with a poor prognosis. Surgery represents the curative treatment for limiting the disease. In the presence of locoregional disease, not suitable for surgery, and for metastastic disease, chemotherapy rep
Autor:
Alain Gelibter, C. F. Pollera, Paolo Carlini, Alessandra Felici, Salvatore De Marco, Francesco Cognetti, Anna Maria Fariello, Isabella Sperduti, Enzo Maria Ruggeri, Teresa Gamucci, Ennio Adami, Luca Moscetti
Publikováno v:
Scopus-Elsevier
Background: It has been demonstrated that the 3-weekly PELF regimen is superior to FAM and FAMTX in advanced gastric cancer. The aim of this multicentric phase II study was to evaluate the efficacy and tolerability of a PELF regimen, given every 2 we
Autor:
Francesco Cognetti, Paolo Carlini, Alessandra Fabi, C. F. Pollera, Anna Ceribelli, S. De Marco
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10(7)
Autor:
V, Lorusso, C F, Pollera, M, Antimi, G, Luporini, C, Gridelli, G L, Frassineti, C, Oliva, M, Pacini, M, De Lena
Publikováno v:
European journal of cancer (Oxford, England : 1990). 34(8)
The aim of this study was to evaluate the efficacy and safety of gemcitabine, a pyrimidine antimetabolite, in the treatment of advanced transitional cell carcinoma of the urinary tract. 35 patients with unresectable or metastatic transitional cell ca
Autor:
C, Martin, C F, Pollera
Publikováno v:
International journal of clinical pharmacology research. 16(1)
Gemcitabine, a novel anticancer agent, has been shown to be active in several human solid tumours, including non-small cell lung cancer and pancreatic cancer. In addition, gemcitabine has been noted to have a particularly mild safety profile for such
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 5(2)
Summary Background Gemcitabine (2′2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses >800 mg/m2/week. Patients and methods The present report summarizes
Autor:
C F, Pollera
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 4(8)